Merus (MRUS) Competitors

Merus (NASDAQ:MRUS) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, community ranking, earnings, valuation, institutional ownership and media sentiment.

Which has more risk & volatility, MRUS or RDY?

Merus has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Which has stronger earnings & valuation, MRUS or RDY?

Dr. Reddy's Laboratories has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merus	$36.13M	86.91	-$154.94M	-$3.27	-13.90
Dr. Reddy's Laboratories	$311.31B	0.04	$668M	$0.63	21.98

Does the media refer more to MRUS or RDY?

In the previous week, Merus had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 15 mentions for Merus and 9 mentions for Dr. Reddy's Laboratories. Merus' average media sentiment score of 1.16 beat Dr. Reddy's Laboratories' score of 1.14 indicating that Merus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merus	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend MRUS or RDY?

Merus currently has a consensus price target of $85.31, suggesting a potential upside of 87.70%. Dr. Reddy's Laboratories has a consensus price target of $17.00, suggesting a potential upside of 22.79%. Given Merus' stronger consensus rating and higher possible upside, research analysts plainly believe Merus is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merus	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.13
Dr. Reddy's Laboratories	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do insiders and institutionals hold more shares of MRUS or RDY?

96.1% of Merus shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 4.6% of Merus shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is MRUS or RDY more profitable?

Dr. Reddy's Laboratories has a net margin of 17.25% compared to Merus' net margin of -680.61%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Merus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merus	-680.61%	-38.89%	-31.16%
Dr. Reddy's Laboratories	17.25%	17.87%	12.32%

Does the MarketBeat Community favor MRUS or RDY?

Merus received 43 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 67.78% of users gave Merus an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote.

Company	Underperform	Outperform
Merus	Outperform Votes 364 67.78%	Underperform Votes 173 32.22%
Dr. Reddy's Laboratories	Outperform Votes 321 59.33%	Underperform Votes 220 40.67%

Summary

Merus beats Dr. Reddy's Laboratories on 12 of the 19 factors compared between the two stocks.